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Abstract
Purpose The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of
metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate 161Tb (T1/2 = 6.89 days;
Eβav = 154 keV) in combination with PSMA-617 as a potentially more effective therapeutic alternative to
177Lu-PSMA-617, due
to the abundant co-emission of conversion and Auger electrons, resulting in an improved absorbed dose profile.
Methods 161Tb was used for the radiolabeling of PSMA-617 at high specific activities up to 100 MBq/nmol. 161Tb-PSMA-617
was tested in vitro and in tumor-bearing mice to confirm equal properties, as previously determined for 177Lu-PSMA-617. The
effects of 161Tb-PSMA-617 and 177Lu-PSMA-617 on cell viability (MTTassay) and survival (clonogenic assay) were compared
in vitro using PSMA-positive PC-3 PIP tumor cells. 161Tb-PSMA-617 was further investigated in therapy studies using PC-3 PIP
tumor-bearing mice.
Results 161Tb-PSMA-617 and 177Lu-PSMA-617 displayed equal in-vitro properties and tissue distribution profiles in tumor-
bearing mice. The viability and survival of PC-3 PIP tumor cells were more reduced when exposed to 161Tb-PSMA-617 as
compared to the effect obtained with the same activities of 177Lu-PSMA-617 over the whole investigated concentration range.
Treatment of mice with 161Tb-PSMA-617 (5.0 MBq/mouse and 10 MBq/mouse, respectively) resulted in an activity-dependent
increase of the median survival (36 vs 65 days) compared to untreated control animals (19 days). Therapy studies to compare the
effects of 161Tb-PSMA-617 and 177Lu-PSMA-617 indicated the anticipated superiority of 161Tb over 177Lu.
Conclusion 161Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to 177Lu-PSMA-617, confirming theo-
retical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of 161Tb. These
data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical
translation of 161Tb-PSMA-617 for the treatment of mCRPC.
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Introduction
The prostate-specific membrane antigen (PSMA) is a cell-
surface glycoprotein that is expressed in normal prostate tissue
and overexpressed in prostate cancer [1, 2]. There are indica-
tions that the expression level of PSMA correlates with the
stage of the disease and the risk of disease progression [3, 4].
PSMA is, therefore, an interesting target to use for radionu-
clide therapy of metastasized castration-resistant prostate can-
cer (mCRPC) [5–8]. The topic of PSMA targeting became
popular with the development of small-molecule-based
radioligands [9]. Initial compounds were designed for
radioiodination, suitable for nuclear imaging, and the first to
be used therapeutically in patients [10]. Subsequently, PSMA
ligands were developed with a chelator to allow their use in
combination with radiometals for both imaging and therapeu-
tic purposes [5, 8, 11]. PSMA-617 and PSMA I&T, equipped
with a DOTA and DOTAGA chelator, respectively, have been
used for targeted radionuclide therapy of mCRPC in clinics [7,
12, 13]. For this purpose, they were mostly labeled with 177Lu
(T1/2 = 6.65 d; Eβav = 134 keV; Eγ = 113 keV, I = 6.17%,
Eγ = 208 keV, I = 10.36%), which is currently the most-
often applied radiometal for therapeutic purposes in the clinics
[14]. In specific cases, 225Ac-PSMA-617 was employed for
the treatment of patients at end-stage without further treatment
options [15–17]. 225Ac decays with a half-life of 10 days,
emitting several α- and β¯-particles while decaying via a
sequence of radioactive daughter nuclides [18]. Although the
results obtained with 225Ac-PSMA-617 were impressive, un-
desired side effects— referring to irreversible damage of sal-
ivary and lacrimal glands — have been reported [17]. The
question arises, therefore, whether alternative radiometals
could be used for targeted radionuclide therapy of mCRPC
which would be potentially more powerful than the
currently-employed 177Lu, without causing additional side-
effects.
In this work, we investigated 161Tb, a recently-introduced
radiolanthanide for therapeutic applications [19]. 161Tb de-
cays with a half-life of 6.89 days to stable 161Dy, while emit-
ting β¯-particles (Eβav = 154 keV) suitable for therapeutic
purposes and γ-radiation (Eγ = 49 keV, I = 17.0%; Eγ =
75 keV, I = 10.2%) useful for SPECT imaging. In this regard,
161Tb closely resembles 177Lu, even though the emitted γ-
radiation is of lower energy. 161Tb also emits a substantial
number of low-energy conversion and Auger electrons, which
makes this radionuclide exceptionally interesting for the treat-
ment of disseminated cancers with multiple metastases rang-
ing from a single cell (diameter: ~10 μm) tomicro cell clusters
(diameter: < 1 mm) [20]. Monte Carlo simulations performed
by Hindié et al. to assess the dose delivered to 10-μm spheres
revealed a 3.5-fold increased value when using 161Tb as com-
pared to 177Lu [21]. In larger tumors (diameter > 10 mm), the
emitted electron energy from 161Tb and 177Lu respectively is
almost entirely absorbed, resulting in a 1.3-fold higher
absorbed electron energy fraction per decay for 161Tb (total
electron emission of 197 keV/decay) compared to 177Lu
(147 keV/decay), making 161Tb more potent than 177Lu [21].
An additional advantage of 161Tb over 177Lu may be the ex-
istence of diagnostic counterparts, including 152Tb (T1/2 =
17.5 h; Eβ+av = 1140 keV, I = 20.3%) and
155Tb (T1/2 = 5.32
d; Eγ = 87 keV, 32.0%, 105 keV, I = 25.1%) for PET and
SPECT imaging respectively, potentially enabling pre-
therapeutic dosimetry with chemically identical radiopharma-
ceuticals [22–25]. The results of theoretical calculations per-
formed by Champion and co-workers also indicate that 161Tb
outperforms other clinically employed (177Lu, 90Y) and non-
standard therapeutic radionuclides (47Sc, 67Cu) with regard to
the dose delivery to small lesions [21, 26].
The production of 161Tb via the 160Gd(n,γ)161Gd→ 161Tb
nuclear reaction was previously reported by Lehenberger et al.
[19]. At the Paul Scherrer Institute (PSI), the method of pro-
cessing Gd targets irradiated in high neutron flux reactors
(RHF, Institut Laue-Langevin, Grenoble, France or
SAFARI-1, Necsa, Pelindaba, South Africa) or at a spallation
neutron source (SINQ, PSI, Switzerland) was implemented
some years ago [22]. The chemical separation of 161Tb from
the target material has since been further developed and opti-
mized at PSI.
The topic of the present study was to investigate 161Tb with
regard to its application for radionuclide therapy. 161Tb was,
therefore, used to label PSMA-617 to enable preclinical com-
parison with 177Lu-PSMA-617. The in-vitro experiments and
biodistribution studies in PC-3 PIP/flu tumor-bearing mice
were performed to confirm equal chemical and pharmacoki-
netic properties of 161Tb-PSMA-617 and 177Lu-PSMA-617
respectively. Importantly, the effect of 161Tb-PSMA-617 was
compared to that obtainedwith 177Lu-PSMA-617 bymeans of
in-vitro cell viability and survival assays, and the therapeutic
effect of 161Tb-PSMA-617 was shown in vivo using tumor-
bearing mice.
Materials and methods
Production and chemical separation of 161Tb
161Tb was produced as previously reported [22]. Enriched
160Gd targets were irradiated over a period of 1–2 weeks at
the SAFARI-1 reactor at Necsa, Pelindaba, South Africa, or at
the RHF at Institut Laue–Langevin, Grenoble, France. In
some cases, 3-week irradiations were performed at the
spallation-induced neutron source SINQ, PSI, Switzerland.
161Tb was chemically separated from the Gd target material
and impurities by cation exchange chromatography, using an
optimized method of the previously-published process
(Supplementary Material) [19, 22].
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Preparation and in-vitro evaluation
of 161Tb-PSMA-617
The radiolabeling of PSMA-617 (Advanced Biochemical
Compounds, ABX GmbH, Radeberg, Germany) with 161Tb
was performed under standard labeling conditions
(Supplementary material). The stability of 161Tb-PSMA-617,
incubated in saline (250 MBq/500 μL), was investigated over
a period of 24 h at room temperature (Supplementary materi-
al). The n-octanol/PBS distribution coefficient (logD) was de-
termined for 161Tb-PSMA-617 (Supplementary material). All
of these experiments were performed as previously reported
for 177Lu-PSMA-617 [27].
Tumor cell uptake and internalization studies
Uptake and internalization studies of 161Tb-PSMA-617 and
177Lu-PSMA-617 were performed, as previously reported,
using PSMA-positive PC-3 PIP and PSMA-negative PC-3
flu tumor cells (provided by Prof. Dr. Martin Pomper; John
Hopkins University, Baltimore, USA) (Supplementary mate-
rial) [27].
Cell viability assay (MTT assay) and cell survival assay
(clonogenic assay)
Tumor cell viability of PC-3 PIP/flu tumor cells upon expo-
sure to 161Tb-PSMA-617 and 177Lu-PSMA-617 (0.01–
20 MBq/mL) was assessed using a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as de-
scribed by Mosmann [28], and performed according to a
previously-reported procedure [29]. The survival of PC-3
PIP/flu tumor cells upon exposure to 161Tb-PSMA-617 and
177Lu-PSMA-617 (0.01–10 MBq/mL) was determined using
the clonogenic assay, as described by Franken et al. [30], and
performed according to a previously-reported procedure [31].
The detailed methods of these studies, including dosimetric
calculations, are described in the Supplementary material. The
results were analyzed for statistical significance by a two-way
ANOVA with Sidak’s multiple comparison post-test using
Graph Pad Prism (version 7).
In-vivo studies
In-vivo experiments were approved by the local veterinarian
department and conducted in accordance with the Swiss law
of animal protection. Athymic nude BALB/c mice were ob-
tained from Charles River Laboratories (Sulzfeld, Germany)
at the age of 5–6 weeks.Mice were subcutaneously inoculated
with PC-3 PIP tumor cells (6 × 106 cells in 100 μL Hank’s
balanced salt solution (HBSS) with Ca2+/Mg2+) and PSMA-
negative PC-3 flu tumor cells (5 × 106 cells in 100 μL HBSS
with Ca2+/Mg2+) on the right and left shoulder, respectively,
for biodistribution and SPECT imaging studies. Therapy stud-
ies were performed with mice inoculated with PC-3 PIP cells
(4 × 106 cells in HBSS with Ca2+/Mg2+) on the right shoulder
(Supplementary material).
Biodistribution studies
Biodistribution studies were performed 12–14 days after tu-
mor cell inoculation when the tumor xenografts reached an
ave rage tumor vo lume of abou t ~50–200 mm3
(Supplementary material). PSMA-617 was labeled with
161Tb at a specific activity of 5.0 MBq/nmol and diluted in
saline. Tumor-bearing mice were intravenously injected with
161Tb-PSMA-617 (5.0MBq, 1 nmol, 100 μL). The mice were
sacrificed at 1 h, 4 h, 24 h, 48 h, or 96 h post injection (p.i.) and
selected tissues and organs were collected, weighed, and mea-
sured using a γ-counter (Perkin Elmer, Wallac Wizard 1480).
Groups of 3–5 mice were sacrificed at each time point. The
results were decay-corrected and listed as percentage of the
injected activity per gram of tissue mass (% IA/g). Data are
presented as the average ± standard deviation (SD).
The data were compared with those previously obtained for
177Lu-PSMA-617 [27] and analyzed for significance using a
one-way ANOVAwith Tukey’s multiple comparison post-test
using GraphPad Prism software (version 7). A p-value of
< 0.05 was considered statistically significant.
Dosimetry estimations
The mean specific absorbed doses (Gy/MBq) to the tumor
xenografts and the kidneys were estimated for 161Tb-PSMA-
617 and 177Lu-PSMA-617 (Supplementary material). The tis-
sue distribution profile of 161Tb-PSMA-617 was considered
as equal to the previously-determined biodistribution data of
177Lu-PSMA-617 [27, 32]. The [% IA/g] values were convert-
ed to non-decay corrected values using the respective half-
lives of the radionuclides to obtain time-integrated activity to
infinity. The mean absorbed energy per decay to cells in the
cell viability study was calculated using Monte Carlo simula-
tions with PENELOPE-2014 [33].
SPECT/CT imaging studies
In a separate study, SPECT/CT experiments were per-
formed 12–14 days after tumor cell inoculation using a
dedicated small-animal SPECT/CT camera (NanoSPECT/
CTTM, Mediso Medical Imaging Systems, Budapest,
Hungary) as previously reported (Supplementary materi-
al) [34]. 161Tb-PSMA-617 (~25 MBq/nmol) was diluted
in saline for injection. Scans were acquired at 1 h, 4 h,
and 24 h after injection of the radioligands (~25 MBq,
1 nmol, 100 μL). During the in-vivo scans, mice were
anesthetized using a mixture of Isoflurane and oxygen.
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Therapy study
Three groups of mice (n = 6) were injected with only
saline, 161Tb-PSMA-617 (5.0 MBq; 1 nmol/mouse), or
161Tb-PSMA-617 (10 MBq; 1 nmol/mouse) at Day 0 of
the therapy, 6 days after PC-3 PIP tumor cell inoculation
(Table 1). The mice were monitored by measuring body
weights and the tumor sizes every other day over
12 weeks. Mice were euthanized when pre-defined end-
point criteria were reached, or when the study was ter-
minated at Day 84 (Supplementary material). The rela-
tive body weight (RBW) was defined as [BWx/ BW0],
where BWx is the body weight in gram at a given day x,
and BW0 the body weight in grams at Day 0. The tumor
dimension was determined by measuring the longest tu-
mor axis (L) and its perpendicular axis (W) with a digital
caliper. The tumor volume (V) was calculated according
to the eq. [V = 0.5 * (L * W2)]. The relative tumor vol-
ume (RTV) was defined as [TVx/TV0], where TVx is the
tumor volume in mm3 at a given day x, and TV0 the
tumor volume in mm3 at Day 0.
Assessment of therapy study
The efficacy of the radionuclide therapy was assessed by
the tumor growth delay (TGDx), which was calculated as
the time required for the tumor volume to increase x-fold
over the initial volume at Day 0. The tumor growth delay
index [TGDIx = TGDx(T)/TGDx(C)] was calculated as the
TGDx ratio of treated mice (T) over control mice (C) for
a 2-fold (x = 2, TGD2) and 5-fold (x = 5, TGD5) increase
of the initial tumor volume. Statistical analysis was per-
formed by a one-way ANOVA with Tukey’s multiple
comparison post-test using GraphPad Prism software
(version 7). A value of p < 0.05 was considered statisti-
cally significant. The median survival was calculated by
Kaplan–Meier curves using GraphPad Prism software
(version 7).
Potential early side-effects related to the exposure to radi-
ation were evaluated by the assessment of absolute and rela-
tive (to body and to brain) organ weights, selected clinical
chemistry plasma parameters including creatinine (CRE),
blood urea nitrogen (BUN), alkaline phosphatase (ALP), total
bilirubin (TBIL), and albumin (ALB), as well as via histolog-
ical analysis of bone marrow and salivary glands. The data
were analyzed for statistical significance (Supplementary
material).
Additional in-vivo investigations using
161Tb-PSMA-617
Additional investigations performed in mice that received
161Tb-PSMA-617 or 177Lu-PSMA-617 (2.5 MBq/mouse,
5.0 MBq/mouse or 10 MBq/mouse) 2 days after PC-3 PIP
tumor cell inoculation are reported in the Supplementary
material.
Results
Production of 161Tb
No-carrier-added 161Tb was produced at high activities of 6–
20 GBq (end of irradiation) depending on the irradiation pa-
rameters (neutron flux, irradiation time, and mass of target
material) . The chemical separat ion resulted in a
radionuclidically pure (160Tb < 0.007%) product of high ra-
diochemical purity comparable to commercial, no-carrier-
added 177Lu (Supplementary material, Table S1). 161Tb was
made available at a high-activity concentration (10–20 MBq/
μL) in SuprapurTM HCl (0.05 M) to be used directly for
radiolabeling of PSMA-617.
Radiolabeling, stability and in-vitro properties
Radiolabeling of PSMA-617 with 161Tb was achieved at spe-
cific activities up to 100 MBq/nmol at a radiochemical purity
Table 1 Design of the tumor therapy study
Treatment groups (n = 6) Injected activity1 Calculated absorbed
dose to tumors
Tumor volume Body weight
Day 0 Day 0
(MBq) (Gy) (mm3) (g)
Saline – – 80 ± 17 17 ± 0.4
161Tb-PSMA-617 5.0 27 74 ± 28 17 ± 1.2
161Tb-PSMA-617 10 54 88 ± 27 18 ± 1.0*
1 The quantity of activity of the injection solutions for each group was confirmed by counting an injection sample (100 μL) using the dose calibrator.
* The average body weight of mice injected with 10MBq 161 Tb-PSMA-617 was significantly higher than the average body weight of mice injected with
5.0 MBq 161 Tb-PSMA-617 (p < 0.05).
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of ≥98% (Supplementary material, Fig. S1). 161Tb-PSMA-
617 (50 MBq/nmol; 250 MBq/500 μL) was stable over at
least 1 h (> 98%), but showed radiolytic degradation when
incubated for longer time periods. In the presence of L-ascor-
bic acid, 161Tb-PSMA-617 was stable up to 24 h (≥ 98%) and
did not show any signs of radiolytic degradation
(Supplementary material, Fig. S2). The determination of the
n-octanol/PBS distribution coefficient (logD value) of 161Tb-
PSMA-617 resulted in a value of −3.9 ± 0.1 (Supplementary
material).
Internalization studies
The PC-3 PIP tumor cell uptake of 161Tb-PSMA-617 (47–
54%) and the internalized fraction (8–11%) after 2–4 h incu-
bation was comparable to the data obtained with 177Lu-
PSMA-617 (49–58% and 9–12%, respectively). The uptake
in PC-3 flu tumor cells was < 0.5% for both 161Tb-PSMA-617
and 177Lu-PSMA-617, respectively (Supplementary material,
Fig. S3).
In-vitro tumor-cell viability and survival
The reduction of viability and survival of PC-3 PIP tumor cells
after exposure to 161Tb-PSMA-617 and 177Lu-PSMA-617
correlated with the applied activity concentration. 161Tb-
PSMA-617 was significantly more effective in reducing the
tumor-cell viability (determined by MTT assays) and survival
(determined by clonogenic assays) as compared to 177Lu-
PSMA-617 when applied at activity concentrations in the
range of 0.1–10 MBq/mL (p < 0.05) and 0.05–5.0 MBq/mL
(p < 0.05) respectively (Fig. 1a/b). Under the given experi-
mental conditions, the mean absorbed energy to tumor cells
in MTT assays was calculated to be 3.2–4.2-fold higher for
161Tb than for 177Lu. Lower values reflect the situation for cell
monolayers, whereas the higher value refers to the “single-cell
situation” which was more the case during the treatment, par-
ticularly in the setting of the clonogenic assay where the cell
number per well was low. The viability of PSMA-negative
PC-3 flu cells was not affected when the radioligands
were applied at concentrations of up to 10 MBq/mL.
Only a slight reduction that was equal for both
radioligands (p > 0.05) was detected at the highest con-
centration (20 MBq/mL). The survival of PC-3 flu cells
was, however, affected at radioligand concentrations of
1 MBq/mL and higher, with a tendency of a more pro-
nounced effect from 161Tb-PSMA-617 (p > 0.05) (Fig.
1c/d). The viability and survival of PC-3 PIP tumor cells
exposed to 161Tb-DPTA and 177Lu-DTPA were not af-
fected, and showed only a marginal reduction at higher
radioligand concentration, which was equal for both ra-
dionuclide complexes (p > 0.05) (Fig. 1e/f).
Biodistribution studies and dose estimation
Time-dependent biodistribution of 161Tb-PSMA-617 was
assessed in PC-3 PIP/flu tumor-bearing mice and compared
to the data previously obtained with 177Lu-PSMA-617
(Supplementary material, Table S2) [27, 32]. The uptake of
161Tb-PSMA-617 in PC-3 PIP tumor xenografts reached a
maximum at 4 h p.i. (49 ± 5.5% IA/g) and decreased slowly
over time (22 ± 4.3% IA/g at 96 h p.i.). Accumulation of
161Tb-PSMA-617 in PC-3 flu tumors and other non-targeted
organs was in the range of blood activity levels or below at
any evaluated time point. The radioligand was cleared via the
kidneys over the first few hours after injection (9.6 ± 1.3% IA/
g; 1 h p.i. 2.9 ± 0.14% IA/g; 4 h p.i.). These results confirmed
that the tissue distribution profile of 161Tb-PSMA-617 was
equal (p > 0.05) to the data previously published for 177Lu-
PSMA-617 (Fig. 2) [27, 32].
For the absorbed dose estimations, the absorbed fractions
of the assumed spherical tumors (80 mm3) were almost equal,
with 0.96 and 0.93 for 161Tb and 177Lu respectively. The es-
timated mean specific absorbed dose to the PC-3 PIP tumors
was 5.34 Gy/MBq and 3.90 Gy/MBq for 161Tb-PSMA-617
and 177Lu-PSMA-617 respectively. This resulted in 27 Gy
(5.0MBq/mouse) and 53 Gy (10 MBq/mouse) in mice treated
with 161Tb-PSMA-617, and would result in 20 Gy (5.0 MBq/
mouse) and 39 Gy (10 MBq/mouse) if mice were treated with
177Lu-PSMA-617. The mean specific absorbed dose to the
kidneys for 161Tb and 177Lu was determined as 0.062 Gy/
MBq and 0.045 Gy/MBq respectively, resulting in 0.31 Gy
(5.0MBq/mouse) and 0.62 Gy (10MBq/mouse) in mice treat-
ed with 161Tb-PSMA-617. Should 177Lu-PSMA-617 be used,
it would result in a kidney dose of 0.225 Gy (5.0MBq/mouse)
and 0.45 Gy (10 MBq/mouse) respectively.
SPECT/CT imaging
SPECT/CT scans of PC-3 PIP/flu tumor-bearing mice
were obtained at 1 h, 4 h, and 24 h after injection of
~25 MBq 161Tb-PSMA-617, resulting in images that
were comparable to those previously obtained with
177Lu-PSMA-617 (Fig. 3) [27]. Radioligand accumula-
tion was visualized in the PC-3 PIP tumor xenograft on
the right side, while negligible uptake was seen in the
PSMA-negative PC-3 flu tumor on the left side. Renal
excretion of 161Tb-PSMA-617 was fast and the activity
almost entirely excreted after 4 h.
Preclinical tumor therapy
Constant tumor growth over time was observed in un-
treated mice of the control group, resulting in three mice
that reached the endpoint at Day 18. The tumor growth
of mice treated with 5.0 MBq and 10 MBq 161Tb-PSMA-
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617 was delayed, and hence the first mouse from these
groups had to be euthanized at Day 30 and Day 42
respectively. The mice from the group treated with
5.0 MBq 161Tb-PSMA-617 were terminated when the
last mouse of the group reached the endpoint at Day
66; however, in the group treated with 10 MBq 161Tb-
PSMA-617, two mice were still alive at the end of the
study at Day 84 (Table 2; Fig. 4). The tumor response in
mice that received 10 MBq 161Tb-PSMA-617 was highly
variable among the six mice, ranging from similar effects
to those observed after injection of 5.0 MBq 161Tb-
PSMA-617 to complete tumor remission (Fig. 5).
Fig. 1 Results of the PC-3 PIP/flu
tumor (a/c/e) cell viability and (b/
d/f) survival studies. a, b
Percentage of PC-3 PIP tumor cell
viability and survival using 161Tb-
PSMA-617 and 177Lu-PSMA-
617 compared to untreated
control cells (set to 100%
viability; average ± SD). c, d
Percentage of PC-3 flu tumor cell
viability using 161Tb-PSMA-617
and 177Lu-PSMA-617 compared
to untreated control cells (set to
100% viability; average ± SD). e,
f Percentage of PC-3 PIP tumor
cell viability using 161Tb-DTPA
and 177Lu-DTPA compared to
untreated control cells (set to
100% viability; average ± SD). *
indicates the range where
significantly different data was
obtained for 161Tb-PSMA-617
and 177Lu-PSMA-617 (p < 0.05).
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The median survival time of mice treated with 161Tb-
PSMA-617 was 36 days, which was clearly longer than the
median survival of the control mice (19 days). The application
of 10 MBq 161Tb-PSMA-617 increased the median survival
of mice to 65 days. In two of the six cases of this group, the
PC-3 PIP tumors disappeared entirely, so that the mice sur-
vived over 12 weeks without any signs of tumor regrowth
(Figs. 4 and 5).
Monitoring of mice during therapy
In the group of mice that received 10MBq 161Tb-PSMA-617,
the body weight was slightly higher than in the other two
groups at therapy start. While control mice and mice that re-
ceived 5.0 MBq 161Tb-PSMA-617 experienced body weight
loss over time, the body weight of mice that received 10 MBq
161Tb-PSMA-617 remained stable (Supplementary material,
Table S3). In line with this result, the average absolute organ
mass, calculated for kidney, liver and spleen of these mice,
were also higher compared to those recorded in mice from the
two other groups. The same held true for these organ masses
calculated relative-to-body mass and relative-to-brain mass
(Supplementary material, Table S3/S4). This indicates that
exposure to 161Tb-PSMA-617 at 10MBq per mouse mitigated
the detrimental effects on the general health status observed in
the other groups, which were probably caused by the rapidly
growing tumors.
Evaluation of selected clinical chemistry parameters of re-
nal and hepatic function (CRE, BUN ALP, TBIL, ALB) and
the histological analysis of the bone marrow and salivary
glands revealed no meaningful difference between the differ-
ent groups (Supplementary material, Tables S5/S6).
Fig. 2 Biodistribution data of
161Tb-PSMA-617 in comparison
to 177Lu-PSMA-617 in PC-3 PIP/
flu tumor-bearing mice until 96 h
p.i. (average ± SD, n = 3–5). a
Uptake in PC-3 PIP tumors
(PSMA positive). b Uptake in
PC-3 flu tumors (PSMA
negative). c Blood activity levels.
d uptake in muscles. e Renal
retention and f uptake in the liver.
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Additional investigations
A better tumor response to 161Tb-PSMA-617 treatment as com-
pared to 177Lu-PSMA-617 was demonstrated in additional pre-
clinical studies. In this case, mice received the radioligands al-
ready 2 days after PC-3 PIP tumor cell inoculation when the
tumor tissue was not yet developed (Supplementary material;
Table S7; Fig. S4). There was a clear trend of enhanced tumor
growth inhibition and increased survival after application of
161Tb-PSMA-617 as compared to 177Lu-PSMA-617 at all activ-
ity levels (Supplementary material, Fig. S4/S5, Table S8).
Discussion
In this study, 161Tb was investigated as a potential alternative to
177Lu to be used in combination with PSMA-targeting ligands.
The production of no-carrier-added 161Tb has been developed to
a quality that is comparable to that of no-carrier-added 177Lu,
enabling efficient radiolabeling of biomolecules under the same
experimental conditions. Attempts to label PSMA-617 with
161Tb at specific activities up to 100 MBq/nmol resulted in ra-
diochemically pure 161Tb-PSMA-617 (> 98%). The radiolytic
degradation of 161Tb-PSMA-617 was similar to 177Lu-PSMA-
617, indicating that the emitted conversion and Auger electrons
did not play a critical role with regard to the radioligand’s
stability.
In agreement with previously-performed studies that com-
pared 161Tb- and 177Lu-folate conjugates [29], the in-vitro prop-
erties of 161Tb-PSMA-617 and 177Lu-PSMA-617 were largely
the same. This included the n-octanol/PBS distribution coeffi-
cient and cell uptake and internalization in PSMA-positive and
PSMA-negative tumor cells. It was also confirmed that the phar-
macokinetics of 161Tb-PSMA-617 was equal to 177Lu-PSMA-
617, resulting in the same biodistribution profiles as expected
(Fig. 2). It is likely that these findings can be extrapolated to
Fig. 3. SPECT/CT images of
mice after injection of ~25 MBq
161Tb-PSMA-617 shown as
maximum intensity projections. a
Scan obtained 1 h p.i.. b Scan
obtained 4 h p.i.. c Scan obtained
24 h p.i..
Table 2 Various parameters
characterizing the efficacy of the
treatment
Treatment Injected
activity
First mouse
euthanized
Last mouse
euthanized
Median
survival
TGDI2 TGDI3
(MBq) (Day) (Day) (Day)
Saline – 18 24 19 1.0 ± 0.4 1.0 ± 0.1
161Tb-PSMA-617 5.0 30 66 36 4.2 ± 1.2 2.5 ± 0.6
161Tb-PSMA-617 10 42 841) 65 n.d. n.d.
1 all mice were euthanized at the end of the study at Day 84 even though 2 mice had not reached an endpoint.
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any targeting agent with a DOTA-chelator; thus, 161Tb could
replace 177Lu for any given biomolecule without changing its
pharmacokinetic profile.
The enhanced therapeutic effects of 161Tb compared to
177Lu became obvious from in-vitro data where the exposure
to 161Tb-PSMA-617 reduced the viability and survival of PC-
3 PIP tumor cells in an activity-dependent manner. In agree-
ment with dosimetric calculations, 161Tb-PSMA-617 was up
to 3-fold more effective than 177Lu-PSMA-617 in vitro. This
difference in efficacy of 161Tb-PSMA-617 and 177Lu-PSMA-
617 was not observed when using PSMA-negative PC-3 flu
cells or when PC-3 PIP cells were exposed to the DTPA-
complexes of the two radionuclides. These findings confirmed
that the observed advantage of using 161Tb-PSMA-617 over
177Lu-PSMA-617 is dependent on PSMA binding and inter-
nalization. The in-vitro findings also corroborated previous in-
vitro findings, where 161Tb-folate was more effective in re-
ducing KB tumor cell viability than 177Lu-folate [29].
The treatment of PC-3 PIP tumor-bearing mice with
5.0 MBq and 10 MBq 161Tb-PSMA-617, respectively,
showed an activity-dependent tumor growth inhibition and
prolonged survival of mice. When 161Tb-PSMA-617 was ap-
plied at 10 MBq, the tumor xenografts disappeared entirely in
two out of six mice, which were still alive at study-end after
12 weeks. As no signs of undesired side-effects were detect-
able, higher activities may be used to treat the tumors more
effectively. The tumor growth inhibition and median survival
(TGDI2 = 4.2 ± 1.2; 36 days; Table 2) of mice that received
5.0 MBq 161Tb-PSMA-617 indicated better therapy response
that that achieved in previously-reported results obtained with
5.0 MBq 177Lu-PSMA-617 (TGDI2 = 2.1 ± 0.3, median sur-
vival: 32 days [34]). Individual mice treated with 5.0 MBq
161Tb-PSMA-617 revealed a heterogeneous response pattern,
where the last mouse reached the endpoint at Day 66. In con-
trast, the use of 177Lu-PSMA-617 therapy resulted in the last
mouse to be euthanized at Day 40 [34].
In additional experiments, we simulated the situation of
tumor cells in vivo that have not yet grown to a tissue, in order
to investigate whether the radioligands delayed the formation
of solid tumors (Supplementary material). At that time, a
vascularized tissue was not yet developed, and the measurable
“swelling” could presumably be ascribed to the formation of a
tumor cell cluster. When applied at activities of 2.5 MBq,
5.0 MBq, or 10 MBq, the effect of 161Tb-PSMA-617 was
enhanced when compared to that of 177Lu-PSMA-617, and
re-growth of already disappeared tumors was less frequent
when using 161Tb-PSMA-617 (Supplementary material; Fig.
S4; Table S8). These results confirmed the anticipated im-
proved effect of 161Tb over 177Lu also at the level of single
cancer cells or cancer cell clusters in vivo.
In line with these results, the dosimetry analysis revealed
that 161Tb has a 1.4-fold higher energy deposition in
established tumors compared to 177Lu. This ratio increases
to about 4-fold for small cell clusters and single cells.
Together with the biological results obtained in this study,
the dosimetry confirms that 161Tb may be better suited than
177Lu for sterilizing small cell clusters in advanced metastatic
prostate cancer with radiolabeled PSMA ligands.
To date, it remains unclear to what extent the design of the
targeting ligand could contribute to fully exploiting the decay
properties of 161Tb. It has been stated in literature that nuclear
localization is necessary to obtain effective Auger electron
therapy [35–38]. In the case of 161Tb, the additional effect is,
however, given predominantly by the emission of conversion
Fig. 4 Graphs representing tumor growth and survival of control mice
(blue) and mice treated with 161Tb-PSMA-617 (red and dark red) with
each group comprising of n = 6 mice. a Average tumor size shown until
the first mouse of each group reached an endpoint; untreated control mice
(blue), mice injected with 5.0 MBq 161Tb-PSMA-617 (red) and mice
injected with 10 MBq 161Tb-PSMA-617 (dark red). b Kaplan–Meier
plot with survival curves of control mice (19 days), mice treated with
5.0 MBq 161Tb-PSMA-617 (36 days) and 10 MBq 161Tb-PSMA-617
(65 days)days), respectively.
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electrons of an energy and tissue range comparable to β¯-
particles of lowest energy. Hence, even when neglecting
Auger electrons, the absorbed dose of 161Tb is still superior
to that of 177Lu due to more emitted electrons per decay. It
remains to be investigated whether PSMA ligands, compris-
ing a nuclear localizing signal for effective delivery of the
radionuclide to the cell nucleus, would improve the effect of
161Tb further by also making full use of the emitted Auger
electrons. More sophisticated ligand designs and more
clinically-relevant mouse models for testing the effects will
be the topic of future preclinical studies to obtain answers to
these open questions.
Conclusion
161Tb was used for the first time with a PSMA ligand, which
demonstrated better results than 177Lu-PSMA-617 in vitro and
in vivo. Based on these findings, the postulated superiority of
161Tb over 177Lu was corroborated. Our preclinical research
activities will be continued to further investigate 161Tb, as we
intend to translate it to clinics and provide prostate cancer
patients with an optimized treatment option in the near future.
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